Efficacy and Safety of Nicorandil in Preventing Contrast-Induced Nephropathy after Elective Percutaneous Coronary Intervention: A Pooled Analysis of 1229 Patients

Table 1

Characteristics of each included trials.

Study	No. of patients^a	Country	Contrast agent	Nicorandil administration	Jadad
Nawa [15]	106/107	Japan	Iomeprol or iohexol	Intravenous administration	4
Fan [14]	120/120	China	Ultravist	Oral administration	4
Iranirad [13]	64/64	Iran	Iohexol	Oral administration	4
Cheng [12]	105/208	China	Ultravist	Intravenous administration	4
He [11]	43/42	China	Iohexol	Intravenous administration	3
Zhang [10]	125/125	China	Ioversol	Oral administration	5

^aThe values are represented as nicorandil group/control group.